These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 16965212

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML, Gurka MJ, Goodkin HP.
    Neurology; 2007 May 01; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.
    Weaver J, Willy M, Avigan M.
    AAPS J; 2008 May 01; 10(1):35-41. PubMed ID: 18446503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E, Girardi A, Poluzzi E, Forcesi E, Menniti-Ippolito F, Mazzanti G, De Ponti F.
    Drug Saf; 2018 Aug 01; 41(8):745-752. PubMed ID: 29582393
    [Abstract] [Full Text] [Related]

  • 9. A drug is not a drug is not a drug: a commentary.
    Struijker Boudier HA.
    Pharmacoepidemiol Drug Saf; 2002 Sep 01; 11(6):437-8. PubMed ID: 12426926
    [No Abstract] [Full Text] [Related]

  • 10. Safety in numbers--monitoring risk in approved drugs.
    Okie S.
    N Engl J Med; 2005 Mar 24; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract] [Full Text] [Related]

  • 11. Consistency in the safety labeling of bioequivalent medications.
    Duke J, Friedlin J, Li X.
    Pharmacoepidemiol Drug Saf; 2013 Mar 24; 22(3):294-301. PubMed ID: 23042584
    [Abstract] [Full Text] [Related]

  • 12. Congress investigates FDA's handling of antidepressant safety information.
    Young D.
    Am J Health Syst Pharm; 2004 Nov 01; 61(21):2228, 2230, 2232 passim. PubMed ID: 15552624
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C.
    Pharmacoepidemiol Drug Saf; 2002 Sep 01; 11(6):439-46. PubMed ID: 12426927
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun 03; 58(105):31596-614. PubMed ID: 10171452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.